1Tameda M,Shiraki K,Sugimoto K,et al. Des-γ-carboxy pro- thrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma. Cancer Sci, 2013,104(6):725-731.
2Tan Y,Yin P,Tang L,et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients:potential biomarkers effective for small hepatocellular carcinoma diag- nosis. Mol Cell Proteomics, 2012,11 ( 2 ):M 111.010694.
3Uto H,Kanmura S,Takami Y,et al. Clinical proteomics for liv- disease:a promising approach for discovery of novel biomarkers. Proteome Sci, 2010,31 ; 8:70.
4Li Y,Wu J,Zhang W,et al. Identification of serum CCL15 in hepatoeellular carcinoma. Br J Cancer,2013,108( 1):99-106.
6Yang M,Chen G,Dang Y,et al. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients.Ups J Med Sci, 2010, 115(4): 232-237.
7Szabo G,Bala S. MicroRNAs in liver disease. Nat Rev Gas-troenterol Hepatol, 2013,10(9 ):542-552.
8Gailthouste L,Ochiva T. Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma. Histol Histopathol,2013,28(4):437-451.
9Giordano S,Columbano A. Micro RNAs:new tools for diagnosis, prognosis,and therapy in hepatocellular carcinoma. Hepatology, 2013,57(2):840-847.
10Moriya S,Morimoto M,Numata K,et al. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellu- lar carcinoma. Anticancer Res, 2013,33 ( 3 ):997-1001.
4Aquilina-Beck A,Ilagan K,Liu Q,etal. Nodal signaling is required for closure of the anterior neural tube in zebrafish. BMC Dev Biol,2007,7:126.
5Strizzi L,Postovit LM,Margaryan NV,et al. Nodal biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol, 2009,4( 1 ): 67-78.
6Adkins HB,Bianco C,Schiffer SG,et al. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.J Clin Invest, 2003,112(4 ) :500-502.
7Postovit LM,Margaryan NV,Seftor EA,et al. Human embryonic stem cell microen -vironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA, 2008,105( 11 ):4329-34.
8Asayama Y,Taguchi KIK,Aishima SIS,et al.The mode of tu- mour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohisto-chemical analysis of E- cadherin,alpha -catenin and beta -catenin. Liver,2002,22 ( 1 ): 43-50.
9Liu WB,Xu GL,Jia WD,et al. Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma. Med 0nc01,2010,19:124-128.
10Xu J,Chen X. Expression of twist gene in primary liver cancer. J Huazhong Univ Sci Technolog Med Sci,2007,27(6): 668-670.
